دورية أكاديمية

Identifying D-positive donors using a second automated testing platform.

التفاصيل البيبلوغرافية
العنوان: Identifying D-positive donors using a second automated testing platform.
المؤلفون: Goldman M; MD (corresponding author), Executive Medical Director, Donor and Transplantation Services., Resz I, Cote J, Ochoa G, Angus N
المصدر: Immunohematology [Immunohematology] 2013; Vol. 29 (3), pp. 97-100.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Red Cross Country of Publication: United States NLM ID: 8806387 Publication Model: Print Cited Medium: Print ISSN: 0894-203X (Print) Linking ISSN: 0894203X NLM ISO Abbreviation: Immunohematology Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Washington, D.C.] : American Red Cross, [1984-
مواضيع طبية MeSH: Blood Donors* , Blood Transfusion* , Genotype*, Blood Grouping and Crossmatching/*instrumentation , Genotyping Techniques/*instrumentation , Rh-Hr Blood-Group System/*isolation & purification, Adult ; Alleles ; Automation, Laboratory/instrumentation ; Blood Grouping and Crossmatching/methods ; Exons ; Female ; Genotyping Techniques/methods ; Humans ; Middle Aged ; Phenotype ; Rh-Hr Blood-Group System/genetics ; Rh-Hr Blood-Group System/immunology
مستخلص: Because of the variability of D expression, one method may be inadequate to correctly classify donors with variant RHD alleles. We evaluated the use of a solid -phase automated platform (ImmucorGamma Galileo) to confirm D- test results obtained on first-time donors on the Beckman Coulter PK7300 automated microplate test system. Samples with discordant results were analyzed by serologic tube methods, RHD genotyping using the BLOODchip platform (Progenika) and, if necessary, sequencing. We estimated the number of cases of alloimmunization in women younger than 50 years likelyto be prevented by the addition of Galileo testing. From May 2011 to May 2012, 910,220 donor samples were tested; 15,441 were first-time donors with concordant D- results. Five donors tested D- on the PK7300 and weak D+ on the Galileo; one was found to be a false positive on further testing. On manual testing, the other four donors had positive indirect antiglobulin test results with one to three of the antisera used and were C+. On BLOODchip testing, two donors were classified as D+, and two were assigned a "no call". D variants included weak D type 67, weak D type 9, and two novel variants. Approximately 10 percent of D- units are transfused to women younger that 50 years. Assuming an alloimmunization rate of 30 percent, use of the Galileo would prevent approximately one alloimmunization every 5 to 6 years in this patient group. We conclude that the yield of preventing alloimmunization in this population by adding a second automated seologic testing platform is very low.
المشرفين على المادة: 0 (Rh-Hr Blood-Group System)
تواريخ الأحداث: Date Created: 20131212 Date Completed: 20140131 Latest Revision: 20161021
رمز التحديث: 20240628
PMID: 24325169
قاعدة البيانات: MEDLINE